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Purpose of the study
Despite recent advances in the reduction of morbidity and
mortality after the advent of HAART, a large number of
HIV patients still present late with advanced immunode-
ficiency. In these patients the risk of developing AIDS-
defining events (ADE) may depend on a solid immune
reconstitution with immune-discordant responses being
at higher risk. We aimed to determine risk factors for the
development of ADE in patients who begin fully suppres-
sive antiretroviral treatment with CD4 counts <200 cells/
μl.
Methods
Data of 1,576 treatment-naive patients starting HAART
after January 1, 1996 at a CD4 count <200 cells/μl were
followed from the date of full viral suppression until viro-
logical failure, the occurrence of a new ADE, loss of fol-
low-up or December 31, 2007, whichever occurred first.
An adjusted Poisson regression model was used to analyze
the incidence rate ratio (IRR) between immune-discord-
ance (all CD4 counts <200 cells/μl) and immune-
response (at least one CD4 count >200 cells/μl) in the
first, second, and third year. In addition, a Cox model was
fitted to analyze risk factors for a new ADE encompassing
all available follow-up data.
Results
In the first year a total of 42 new ADE occurred with an
IRR for immune-discordance of 5.57 (95% CI
2.96–10.48, p < 0.001) in the adjusted Poisson model. In
the second (nine events) and third year (eight events) of
viral control, a non-significant trend towards a lower
influence of immune-discordance was observed (IRR
1.03, 95% CI 0.13–8.26, p = 0.98 and 2.02, 95% CI
0.25–16.41, p = 0.51, respectively). In the Cox model ana-
lyzing 3,633 person-years of follow-up, risk factors for
development of a new ADE included the latest CD4 count
below 50 cells/μl (HR 6.36,95% CI 2.53–15.95, p <
0.001) and CD4 counts between 50–100 cells/μl (HR
3.84,95% CI 1.70–8.68, p = 0.001). No significant influ-
ence of latest CD4 count above 100 cells/μl, CD4 count at
initiation of HAART, sex, age, transmission risk, and
AIDS-defining event prior to initiation of HAART was
observed.
Conclusion
Immune-discordance is a risk factor for a new ADE while
on HAART during the first year of suppressed viremia.
After this time the incidence of ADE decreases dramati-
cally even in patients with prolonged immunodeficiency.
The risk is highest in patients who fail to increase CD4
counts to >100 cells/μl. Strategies to raise or maintain a
CD4 count above at least 100 cells/μl could prevent most
ADE in this patient group. See Figure 1.
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